{"id":746066,"date":"2023-04-07T08:28:01","date_gmt":"2023-04-07T12:28:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/"},"modified":"2023-04-07T08:28:01","modified_gmt":"2023-04-07T12:28:01","slug":"oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/","title":{"rendered":"Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<p>IRVINE, Calif., April  07, 2023  (GLOBE NEWSWIRE) &#8212; Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying DetermaIO\u2122 to samples collected from the randomized Phase II AtezoTRIBE clinical trial in metastatic colorectal cancer (mCRC). The results were published in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=syHrLBg6JeteKdVGSMxataQ8M81RawLfDUJu8QuuenyvSbASTGfZ_8vTnEZAMF9GV6_St-I1KA984D78r5IRRlMlkAAiW_NqyJMeaeDF0AEJIyUwEL7rhLOCZn82mhEukGP6LPFQ_unOfuQiECJbVsv1JLs5VNas0iqriT8IHM-1DnXUvjqO-Ea05PNzhNZBy6jsexHQV1VJtxshOa6zGGLEkMhTIegqPMXGDdv8De3PeACmNvP_BL6VTzLdx44cApr2YPP7q9QYMTnKc2kLlda_vTgGGgttAZdMC1PEeYo=\" rel=\"nofollow noopener\" target=\"_blank\">Clinical Cancer Research<\/a> and showed the utility of DetermaIO in potentially identifying more responders to ICI therapy than current standard of care biomarkers.<\/p>\n<p>Highlights of the peer-reviewed publication include:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">In the overall population (n=122), DetermaIO positive patients achieved better outcomes in terms of progression-free survival from the addition of atezolizumab among mCRC patients than DetermaIO negative patients, regardless of MMR status.<\/li>\n<li style=\"margin-bottom:8pt\">A similar trend was observed in the pMMR population (n=110) that does not currently qualify for ICI therapy in mCRC.<\/li>\n<li style=\"margin-bottom:8pt\">In the pMMR group treated with ICI addition to chemo (N=69), patients that had a very high DetermaIO had a significantly improved progression-free survival (HR=0.19 95%CI: 0.09 &#8211; 0.40). Overlap between DetermaIO positive, dMMR, and TMB is limited, demonstrating DetermaIO identifies a unique subset of patients not identified by these biomarkers.<\/li>\n<\/ul>\n<p>The authors conclude, \u201cOur study demonstrates that the gene expression profiling through the DetermaIO of mCRC would mark a fundamental paradigm shift in the characterization of tumor immune microenvironment of mCRC, by providing the opportunity to identify an immune-enriched tumor microenvironment among pMMR tumors that do not currently qualify for ICI therapy.\u201d<\/p>\n<p>\n        <strong>About Oncocyte <\/strong>\n      <\/p>\n<p>Oncocyte is a precision diagnostics company. The Company\u2019s tests are designed to help provide clarity and confidence to physicians and their patients. DetermaIO\u2122 is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. VitaGraft\u2122 is a blood-based solid organ transplantation monitoring test, and pipeline test DetermaCNI\u2122 is blood-based monitoring tool for monitoring therapeutic efficacy.<\/p>\n<p>DetermaIO\u2122, DetermaCNI\u2122, and VitaGraft\u2122 are trademarks of Oncocyte Corporation<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Jesse Arno<br \/>(949) 409-6770<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cxphTyMvCzfBFi3EBO83gkp_aJrOYEmxSFgdBQeNT5WdvrxAb9N6YwMFV7HQs1lCXtb7gEcktGskyN0YudI8vRuZp4NRcVjqMl2cjr65rv8=\" rel=\"nofollow noopener\" target=\"_blank\">jarno@oncocyte.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDA2MSM1NTE1NzIzIzIwMjYxNzA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NmY3Y2VkMzYtYTBlMS00MmMzLWE3OWItODQ4YzdkYTcyZjVhLTEwMzc3NDI=\/tiny\/Oncocyte-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) &#8212; Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying DetermaIO\u2122 to samples collected from the randomized Phase II AtezoTRIBE clinical trial in metastatic colorectal cancer (mCRC). The results were published in Clinical Cancer Research and showed the utility of DetermaIO in potentially identifying more responders to ICI therapy than current standard of care biomarkers. Highlights of the peer-reviewed publication include: In the overall population (n=122), DetermaIO positive patients achieved better outcomes in terms of progression-free survival from the addition of atezolizumab among mCRC patients than DetermaIO negative patients, regardless of MMR status. A similar trend was observed in the pMMR population &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-746066","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) &#8212; Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying DetermaIO\u2122 to samples collected from the randomized Phase II AtezoTRIBE clinical trial in metastatic colorectal cancer (mCRC). The results were published in Clinical Cancer Research and showed the utility of DetermaIO in potentially identifying more responders to ICI therapy than current standard of care biomarkers. Highlights of the peer-reviewed publication include: In the overall population (n=122), DetermaIO positive patients achieved better outcomes in terms of progression-free survival from the addition of atezolizumab among mCRC patients than DetermaIO negative patients, regardless of MMR status. A similar trend was observed in the pMMR population &hellip; Continue reading &quot;Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-07T12:28:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDA2MSM1NTE1NzIzIzIwMjYxNzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer\",\"datePublished\":\"2023-04-07T12:28:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\\\/\"},\"wordCount\":322,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNDA2MSM1NTE1NzIzIzIwMjYxNzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\\\/\",\"name\":\"Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNDA2MSM1NTE1NzIzIzIwMjYxNzA=\",\"datePublished\":\"2023-04-07T12:28:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNDA2MSM1NTE1NzIzIzIwMjYxNzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNDA2MSM1NTE1NzIzIzIwMjYxNzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer - Market Newsdesk","og_description":"IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) &#8212; Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying DetermaIO\u2122 to samples collected from the randomized Phase II AtezoTRIBE clinical trial in metastatic colorectal cancer (mCRC). The results were published in Clinical Cancer Research and showed the utility of DetermaIO in potentially identifying more responders to ICI therapy than current standard of care biomarkers. Highlights of the peer-reviewed publication include: In the overall population (n=122), DetermaIO positive patients achieved better outcomes in terms of progression-free survival from the addition of atezolizumab among mCRC patients than DetermaIO negative patients, regardless of MMR status. A similar trend was observed in the pMMR population &hellip; Continue reading \"Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-07T12:28:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDA2MSM1NTE1NzIzIzIwMjYxNzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer","datePublished":"2023-04-07T12:28:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/"},"wordCount":322,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDA2MSM1NTE1NzIzIzIwMjYxNzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/","name":"Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDA2MSM1NTE1NzIzIzIwMjYxNzA=","datePublished":"2023-04-07T12:28:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDA2MSM1NTE1NzIzIzIwMjYxNzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDA2MSM1NTE1NzIzIzIwMjYxNzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-colorectal-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=746066"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746066\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=746066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=746066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=746066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}